2016

New Platinum Agents, Triplatin and Triplatin NC, Suppress Advanced Breast and Pancreatic Cancer

Stephanie C. DeMasi  
*Virginia Commonwealth University*

Kazuaki Takabe MD, Ph.D, FACS  
*Virginia Commonwealth University*

Follow this and additional works at: [https://scholarscompass.vcu.edu/mds_posters](https://scholarscompass.vcu.edu/mds_posters)

Part of the [Medicine and Health Sciences Commons](https://scholarscompass.vcu.edu/mds_posters)

Downloaded from  
[https://scholarscompass.vcu.edu/mds_posters/2](https://scholarscompass.vcu.edu/mds_posters/2)

This Poster is brought to you for free and open access by the School of Medicine at VCU Scholars Compass. It has been accepted for inclusion in MD Student Summer Research Fellowship Program Posters by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
New Platinum Agents, Triplatin and Triplatin NC, Suppress Advanced Breast and Pancreatic Cancer

Stephanie C. DeMasi, BS¹, Samantha J. Katner, BS², Eniko Katsuta, MD, PhD¹, Hiroaki Aoki, MD, PhD¹, Erica Peterson, BS², Nicholas P. Farrell, BS, PhD², Kazuaki Takabe, MD, PhD, FACS¹

¹ Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine And Massey Cancer Center, Richmond, VA. ² Department of Chemistry, Virginia Commonwealth University, Richmond, VA.

Purpose

- To examine the efficacy of newly developed, polynuclear platinum agents, that work by a similar mechanism of damaging DNA cross-linking.

Background

- Recently, platinum agents are demonstrating to be an effective therapy against advanced metastatic cancer, though limited by the severe side effects.
- New platinum derivative compounds were developed to have less cytotoxicity, to overcome the severe dose dependent toxicities of the former platinum agents.

Methods

- **In vitro**: Cell proliferations were quantified by CCK8 assay to determine IC50 and drug sensitivity of 4T1-luc2 cells as a murine breast cancer, and Panc02-luc cells as a murine pancreatic cancer.
- **In vivo 4T1 Implantation**: Female Balb/C mice were orthotopically implanted with murine 4T1-luc2 cells (1.0 x 10^4 cells suspended in 20 µL 1:9, PBS:Matrigel) into Rt #2 Mammary Fat Pad ODV. Animals were randomized 24-hours after implantation into 3 groups based on tumor size (defined as day 1). Animals were treated q4 days by I.P. injection with either Triplatin (0.3mg/kg), Triplatin NC (25mg/kg), or Saline. Primary tumor growth was monitored by direct caliper measurement and bioluminescent imaging by injecting D-Luciferin (0.2mL) and analysis of photon emission with Living Image Software.
- **Ex vivo 4T1 Lung Metastasis**: Mice were injected with I.P. luciferon and sacrificed 10 minutes after injection. The lungs were excised and placed in sterile 10cm petri dish. Lungs were imaged at a fixed time point (15 minutes) post injection.
- **In vivo Panc02 Carcinomatosis Implantation**: Generated by I.P. injection of 1 x 10^5 Panc02-luc cells into C57/B6k mice. Animals were randomized and treated q4 days with either Triplatin or saline by I.P. injection. Survival was monitored.

Results

- **Triplatin and Triplatin NC suppressed cell growth of both Breast Cancer and Pancreatic Cancer in a dose dependent manner in vitro.**
- **Triplatin and Triplatin NC suppressed primary Breast Cancer tumor growth and developing lung metastasis in vivo.**
- **Triplatin treatment prolonged survival significantly in the Pancreatic Cancer Carcinomatosis model in vivo.**

Conclusion & Recommendations

- Triplatin and Triplatin NC suppressed cell growth of both Breast Cancer and Pancreatic Cancer in a dose dependent manner in vitro.
- Both Triplatin and TriplatinNC demonstrated growth suppression of the primary breast tumor. A single animal (in the Triplatin NC group) was sacrificed due to weight loss.
- In the advanced ex vivo lung metastasis model our most striking results were observed, where the agents nearly prohibited lung metastasis from occurring.
- In the pancreatic cancer peritoneal carcinomatosis model, Triplatin reduced total tumor burden. Mouse survival was significantly enhanced by the Triplatin treatment group and no mouse developed weight loss more than 25% of body weight.
- The new platinum compounds with less cytotoxicity and favorable pharmacokinetics warrant further investigation to determine their role in advanced metastatic breast cancer and pancreatic carcinomatosis.